Kinnate Biopharma, Inc. sets IPO terms.

An IPO of Kinnate Biopharma, Inc. will take place on December 2, 2020. Kinnate Biopharma is a biopharmaceutical company that is focused on the discovery and development of small molecule kinase inhibitors for difficult to treat, genomically-defined cancers. Kinase inhibition is a proven  approach to control cancer and has been targeted at an increasing number of cancer indications for nearly two decades.Kinases are enzymes that regulate proteins biological activity. Mutated kinases can lead to dysregulation of activity, which leads to proliferation of cancer cells. The company’s most advanced product-candidate is KIN002787, a rapidly accelerated fibrosarcoma (RAF) inhibitor that is being developed for the treatment of patients  with lung cancer, melanoma and other large tumors.
The listed book runners of the IPO are Goldman Sachs, SVB Leerink, Piper Sandler and Wedbush PacGrow.